Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Roivant Sciences Shares Jump 10% in 1 Day Since Positive Phase 3 Results for Brepocitinib

Roivant Sciences Announces Positive Phase 3 Results for Brepocitinib in Non-Infectious Uveitis

+10.07% in 1 day $34.92 when we broke this story → $38.44 at 9:57 AM ET, 22 Oct 2026

Roivant Sciences and its subsidiary Priovant Therapeutics achieved primary and key secondary endpoints in two Phase 3 trials evaluating brepocitinib for non-infectious uveitis. The clinical data demonstrated a statistically significant extension in time to treatment failure, supporting a planned regulatory submission in early 2027.

Eye check, optometry, doctor, optician. Stock photo illustrating Roivant Sciences' other story.
Roivant Sciences Ltd. · Healthcare · Photo: newarta / Pixabay

Key highlights

  • Median time to treatment failure exceeded 48 weeks for brepocitinib versus 12 weeks for placebo
  • Statistically significant p-values of <0.0001 achieved across primary and all key secondary endpoints
  • Steroid-free quiescence at Week 48 reached 62% in the treatment group compared to 20% for placebo
  • Resolution of macular edema observed in 42% of treated eyes versus 4.8% in the control group
  • Supplemental New Drug Application (sNDA) filing scheduled for the first half of calendar year 2027

Phase 3 CLARITY Trial Outcomes

Roivant Sciences and Priovant Therapeutics reported that the Phase 3 CLARITY program met all primary and secondary objectives in treating non-infectious uveitis (NIU). In two identical trials, CLARITY-1 and CLARITY-2, the 45 mg once-daily dose of brepocitinib demonstrated a median time to treatment failure of more than 48 weeks. This result significantly outperformed the placebo group's 12-week median duration. The program also achieved high rates of steroid-free quiescence and resolution of macular edema despite utilizing a more aggressive steroid taper than historical industry trials. Consequently, the company intends to submit a supplemental New Drug Application to the FDA in the first half of calendar year 2027.

Clinical Significance and Patient Impact

  • Establishment of a new benchmark for steroid-sparing benefit in the treatment of chronic ocular inflammation
  • Achievement of therapeutic benefit despite a faster reduction of oral prednisone than precedent NIU trials
  • Significant resolution of macular edema, addressing one of the leading causes of permanent vision loss
  • Validation of the dual TYK2/JAK1 inhibition mechanism in treating debilitating ocular etiologies
  • Maintenance of a safety profile consistent with previous clinical evaluations of the brepocitinib molecule

Expert Perspective on Therapeutic Shift

“The phenomenal results from the Phase 3 CLARITY program suggest that brepocitinib could meaningfully change how we treat non-infectious uveitis across multiple etiologies.”

Quan Dong Nguyen, MD, MSc, Professor of Ophthalmology, Stanford University School of Medicine

Business and Financial Profile

Roivant Sciences operates using a Vant model, where specialized subsidiaries like Priovant Therapeutics develop targeted therapies. The company maintains a robust liquidity position, reporting $3.9 billion in cash and equivalents as of June 30, 2026, which was further bolstered by a $2.25 billion patent settlement with Moderna in July 2026. This capital supports a diverse pipeline, including the recently FDA-approved LISRAYA for dermatomyositis. Roivant currently holds a market capitalization of $25.22 billion. The positive CLARITY data follows other recent milestones, including the announcement of Phase 3 studies for mosliciguat and ongoing developments in cutaneous lupus erythematosus.

Roivant Sciences Ltd. share price · last month
Line chart of Roivant Sciences Ltd.'s share price over the last month, from $34.70 on 19 Oct → $38.61 on 16 Nov; our story on 21 Oct at $34.92.

Up 10.6% since our story on 21 Oct: $34.92 when we broke it → $38.61 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$34.70
20 Oct$34.92
21 Oct$36.80
22 Oct$37.45
23 Oct$36.49
26 Oct$36.05
27 Oct$36.54
28 Oct$37.11
29 Oct$37.52
30 Oct$36.91
2 Nov$35.89
3 Nov$36.04
4 Nov$38.23
5 Nov$36.62
6 Nov$38.88
9 Nov$40.67
10 Nov$41.19
11 Nov$41.85
12 Nov$39.99
13 Nov$39.53
16 Nov$38.61
Earlier announcements by Roivant Sciences Ltd.
DateAnnouncementAmount
23 Sep 2026Topline results from proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosusSource: investor.roivant.com–
08 Sep 2026Positive results from Phase 2 PHocus study of mosliciguat in PH-ILD and announcement of Phase 3 PHrontier studySource: investor.roivant.com–
27 Aug 2026FDA approval of LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositisSource: investor.roivant.com–
06 Aug 2026Financial results for the first quarter ended June 30, 2026, and business updateSource: investor.roivant.com–
20 May 2026Financial results for the fourth quarter and fiscal year ended March 31, 2026Source: investor.roivant.com–
03 Mar 2026Genevant Sciences and Arbutus Biopharma global patent settlement with ModernaSource: investor.roivant.com$2.25 Billion

Management commentary

“The phenomenal results from the Phase 3 CLARITY program suggest that brepocitinib could meaningfully change how we treat non-infectious uveitis across multiple etiologies.”

Quan Dong Nguyen, MD, MSc, Professor of Ophthalmology, Stanford University School of Medicine
Roivant Sciences Ltd. · financial snapshot
Share price$34.92
Market cap$25.2B
Revenue (annual)$8M
1-month price change-12.20%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Roivant Sciences Ltd. announcing positive Phase 3 results for brepocitinib in non-infectious uveitis.

Read the filing ↗

Track Roivant Sciences Ltd. live

Get the next Roivant Sciences Ltd. SEC filing seconds after it lands.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.